Literature DB >> 3114828

Lithium response and the sequence of episode polarities: preliminary report on a Hamilton sample.

E Grof, M Haag, P Grof, H Haag.   

Abstract

This is a preliminary report on a study which replicated the finding of a significant relationship between the response to long-term lithium stabilization and the sequence of episode polarities (depressive/manic) in bipolar and schizoaffective (bipolar) patients. The lithium response and the clinical course data were assessed independently, in a blind manner, utilizing a data collection which has been gathered in earlier studies. There was a significant association between lithium response (stability achieved on long-term lithium treatment) and the sequence of episode polarities. The main determinant of this association was a close link between lithium response and the MDI sequence of episode polarities. The observed association may be explained in several ways: as an artifact; due to the exclusively antimanic effect of lithium; due to true psychobiological differences between mania and depression; as a result of the differences between bipolar type one and type two patients; and finally due to bipolar heterogeneity. Considering the data available to date the explanation via bipolar heterogeneity appears to be the most likely one.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3114828     DOI: 10.1016/0278-5846(87)90060-1

Source DB:  PubMed          Journal:  Prog Neuropsychopharmacol Biol Psychiatry        ISSN: 0278-5846            Impact factor:   5.067


  8 in total

1.  Depression following mania.

Authors:  L Tondo; R J Baldessarini
Journal:  Mol Psychiatry       Date:  2016-04-26       Impact factor: 15.992

Review 2.  A speculative model of affective illness cyclicity based on patterns of drug tolerance observed in amygdala-kindled seizures.

Authors:  R M Post; S R Weiss
Journal:  Mol Neurobiol       Date:  1996-08       Impact factor: 5.590

Review 3.  Rapid cycling bipolar disorder: clinical characteristics and treatment options.

Authors:  William Coryell
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

4.  Early improvement with lithium in classic mania and its association with later response.

Authors:  Rodrigo Machado-Vieira; David A Luckenbaugh; Marcio G Soeiro-de-Souza; Getulio Marca; Ioline D Henter; Joao V Busnello; Wagner F Gattaz; Carlos A Zarate
Journal:  J Affect Disord       Date:  2012-08-17       Impact factor: 4.839

5.  Free Interval Duration: Clinical Evidence of the Primary Role of Excitement in Bipolar Disorder.

Authors:  Gabriele Sani; Alessio Simonetti; Daniela Reginaldi; Alexia E Koukopoulos; Antonio Del Casale; Giovanni Manfredi; Georgios D Kotzalidis; Paolo Girardi
Journal:  Curr Neuropharmacol       Date:  2017-04       Impact factor: 7.363

Review 6.  Depression and Mania in Bipolar Disorder.

Authors:  Leonardo Tondo; Gustavo H Vázquez; Ross J Baldessarini
Journal:  Curr Neuropharmacol       Date:  2017-04       Impact factor: 7.363

7.  A systematic review and meta-analysis of clinical predictors of lithium response in bipolar disorder.

Authors:  T P Hui; A Kandola; L Shen; G Lewis; D P J Osborn; J R Geddes; J F Hayes
Journal:  Acta Psychiatr Scand       Date:  2019-06-30       Impact factor: 6.392

8.  Association of polygenic score for major depression with response to lithium in patients with bipolar disorder.

Authors:  Azmeraw T Amare; Klaus Oliver Schubert; Liping Hou; Scott R Clark; Sergi Papiol; Micah Cearns; Urs Heilbronner; Franziska Degenhardt; Fasil Tekola-Ayele; Yi-Hsiang Hsu; Tatyana Shekhtman; Mazda Adli; Nirmala Akula; Kazufumi Akiyama; Raffaella Ardau; Bárbara Arias; Jean-Michel Aubry; Lena Backlund; Abesh Kumar Bhattacharjee; Frank Bellivier; Antonio Benabarre; Susanne Bengesser; Joanna M Biernacka; Armin Birner; Clara Brichant-Petitjean; Pablo Cervantes; Hsi-Chung Chen; Caterina Chillotti; Sven Cichon; Cristiana Cruceanu; Piotr M Czerski; Nina Dalkner; Alexandre Dayer; Maria Del Zompo; J Raymond DePaulo; Bruno Étain; Stephane Jamain; Peter Falkai; Andreas J Forstner; Louise Frisen; Mark A Frye; Janice M Fullerton; Sébastien Gard; Julie S Garnham; Fernando S Goes; Maria Grigoroiu-Serbanescu; Paul Grof; Ryota Hashimoto; Joanna Hauser; Stefan Herms; Per Hoffmann; Andrea Hofmann; Esther Jiménez; Jean-Pierre Kahn; Layla Kassem; Po-Hsiu Kuo; Tadafumi Kato; John R Kelsoe; Sarah Kittel-Schneider; Sebastian Kliwicki; Barbara König; Ichiro Kusumi; Gonzalo Laje; Mikael Landén; Catharina Lavebratt; Marion Leboyer; Susan G Leckband; Alfonso Tortorella; Mirko Manchia; Lina Martinsson; Michael J McCarthy; Susan L McElroy; Francesc Colom; Marina Mitjans; Francis M Mondimore; Palmiero Monteleone; Caroline M Nievergelt; Markus M Nöthen; Tomas Novák; Claire O'Donovan; Norio Ozaki; Urban Ösby; Andrea Pfennig; James B Potash; Andreas Reif; Eva Reininghaus; Guy A Rouleau; Janusz K Rybakowski; Martin Schalling; Peter R Schofield; Barbara W Schweizer; Giovanni Severino; Paul D Shilling; Katzutaka Shimoda; Christian Simhandl; Claire M Slaney; Alessio Squassina; Thomas Stamm; Pavla Stopkova; Mario Maj; Gustavo Turecki; Eduard Vieta; Julia Veeh; Stephanie H Witt; Adam Wright; Peter P Zandi; Philip B Mitchell; Michael Bauer; Martin Alda; Marcella Rietschel; Francis J McMahon; Thomas G Schulze; Bernhard T Baune
Journal:  Mol Psychiatry       Date:  2020-03-16       Impact factor: 13.437

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.